Shenzhen Hepalink Pharmaceutical Group has been granted a patent for a pancreatin preparation with reduced viral infectivity. The preparation includes pancreatin enzymes and peracetic acid, derived from animal sources like porcine pancreas glands. The enzymatic profile remains unchanged after treatment with peracetic acid. GlobalData’s report on Shenzhen Hepalink Pharmaceutical Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Shenzhen Hepalink Pharmaceutical Group, Transgenic murine models was a key innovation area identified from patents. Shenzhen Hepalink Pharmaceutical Group's grant share as of April 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.

Pancreatin preparation with reduced viral infectivity

Source: United States Patent and Trademark Office (USPTO). Credit: Shenzhen Hepalink Pharmaceutical Group Co Ltd

A recently granted patent (Publication Number: US11952603B2) discloses a pancreatin preparation designed to reduce viral infectivity. The preparation includes one or more pancreatin enzymes and peracetic acid (PAA), with the enzymatic profile remaining unchanged despite the treatment with PAA. Additionally, the pancreatin preparation may also contain porcine pancreas glands to further enhance its efficacy.

The patent claims highlight the effectiveness of the pancreatin preparation in reducing viral infectivity, specifically targeting viruses such as Encephalomyocarditis virus (EMC), Murine Minute Virus (MMV), and Porcine parvovirus (PPV). The preparation demonstrates a significant reduction in viral infectivity compared to untreated samples, showcasing its potential in mitigating the risk of viral contamination. Furthermore, the inclusion of pancreatin enzymes derived from animal sources, such as lipases, proteases, and amylases, further enhances the formulation's pharmaceutical properties. The treatment of these enzymes with PAA prior to extraction ensures a high level of purity and efficacy in the final product.

To know more about GlobalData’s detailed insights on Shenzhen Hepalink Pharmaceutical Group, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies